Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2000
12/26/2000US6166057 Fungicides for the control of take-all disease of plants
12/26/2000US6166056 Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings
12/26/2000US6166055 Antiinflammatory agents
12/26/2000US6166053 Antiproliferative agent for treating cancer
12/26/2000US6166049 A treatment and/or prophylaxis of hyperglycaemia, pre-diabetic insulin resistance syndrome by administering an agonist of peroxisome proliferator-activated receptor to stimulate fatty oxidation
12/26/2000US6166048 Pharmaceutical compositions for inhibition of cytokine production and secretion
12/26/2000US6166046 A synergistic mix ratio
12/26/2000US6166045 A purified torasemide obtained from the acidified solution and crystallization; storage stable and achieves high levels in serum shortly after oral administration
12/26/2000US6166044 Colonic delivery of nicotine to treat inflammatory bowel disease
12/26/2000US6166043 Insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin
12/26/2000US6166042 Pharmaceutical composition
12/26/2000US6166040 Treating a disorder of the central nervous system
12/26/2000US6166039 Peripherally active anti-hyperalgesic opiates
12/26/2000US6166035 1,4-dihydropyridine derivatives and their use in therapy
12/26/2000US6166034 Spiro piperidine derivatives as 5HT1D receptor antagonists
12/26/2000US6166033 Drugs for preventing and treating dopamine d receptor-related morbid states such as schizophrenia and problematic behavior caused by cerebrovascular accidents and senile dementia and do not induce extrapyramidal disorders as side effects
12/26/2000US6166032 Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
12/26/2000US6166031 An inhibitor of 5-lipoxygenase enzyme, a blocking agents of leukotriene receptors; useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction
12/26/2000US6166030 An inhibitors of the neuronal isoform of nitric oxide synthase; treating hypoxia, stroke, ischaemia, neurodegenerative conditions, schizophrenia, pain, migraine
12/26/2000US6166029 Method for treating cancer with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
12/26/2000US6166028 Diaminopuridine-containing thiourea inhibitors of herpes viruses
12/26/2000US6166027 Treatment of high blood pressure and cardiac insufficiency, angina pectoris, arrhythmias, thromboembolic diseases, ischaemias, myocardial infarction, cerebral stroke, restenoses, coronary angioplasties, arteriosclerosis
12/26/2000US6166025 A stable, aqueous drug formulation for treating migraine
12/26/2000US6166024 Via formulations adapted for delayed-release oral or rectal administration
12/26/2000US6166023 1,5- and 3-O-substituted 1H-indazoles having anti-asthmatic, anti-allergic, anti-inflammatory, immunomodulating and neuroprotective action, process for their preparation and their use as medicaments
12/26/2000US6166022 Treatment of platelet aggregation disorders and angina
12/26/2000US6166020 Aryl and heteroaryl alkoxynaphthalene derivatives
12/26/2000US6166018 For treating fungal infection wherein said fungal infection is central candidiasis
12/26/2000US6166017 Method of using ketoconazole and related substances in medicaments for treatment of type II diabetes and methods of treating same
12/26/2000US6166016 Analgesics, anti-inflammatory agents, antimicrobial drugs, hypoglycemic agents, hypolipidemic agents, antihypertensive agents, anti-cancer agents
12/26/2000US6166015 Pyrrolidine derivatives-CCR-3 receptor antagonists
12/26/2000US6166014 Treatment of disease-states characterized by thrombotic activity
12/26/2000US6166012 Quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye
12/26/2000US6166011 For treatment of disorders arising from neurodegenerative diseases or other disorders involving nerve damage
12/26/2000US6166009 For clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which c-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation
12/26/2000US6166008 Treatment of schizophrenia with ampakines and neuroleptics
12/26/2000US6166007 Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
12/26/2000US6166005 Heterocyclic metalloprotease inhibitors
12/26/2000US6166002 Substituted phenylalkenoylguanidines, process for their preparation, and their use in medicaments and in diagnostics
12/26/2000US6166000 For treating breast cancer
12/26/2000US6165999 Tetracycline derivatives
12/26/2000US6165998 Substituted azo and stilbene compounds
12/26/2000US6165997 Phospholipids having antimicrobial activity with or without the presence of antimicrobials
12/26/2000US6165996 Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis
12/26/2000US6165994 Methods for promoting the healing of cutaneous wounds and ulcers using compositions of α-D-glucans
12/26/2000US6165989 An isolated polynucleotide comprising a first polynucleotide or the full complement of the entire length of the first polynucleotide, wherein the first polynucleotide encodes a polypeptide comprising specific amino acid sequence
12/26/2000US6165987 A veterinary parasciticide dose containing a praziquantel, at least one macrolide anthelmintic selected from avermectins and milbemycins and a solvent selected from glycerol formal, ethyl lactate, benzyl alcohol and n-metyl-2-pyrrollidone
12/26/2000US6165984 Administering an effective amount of naringin or naringenin to the human to prevent acylcoa-cholesterol-o-acyltransferase activity to treat hepatic diseases; inhibiting accumulation of macrophage-lipid complex on the arterial endothelium
12/26/2000US6165980 Distamycin derivatives, wherein the distamycin formyl group is substituted by a benzoyl group bearing alkylating group a bis-halo-ethylamino or a n-alkyl-n-haloethyl-amino group, while amidine group is substituted by various nitrogen groups
12/26/2000US6165975 Microdose therapy
12/26/2000US6165974 Administering an effective dose of a pharmaceutical preparation comprising at least two coagulation factors which are components of a prothrombinase or of a pro-prothrombinase to the patient for the treatment of acute bleeding
12/26/2000US6165791 Nucleotide sequences which prevent the transcription of genes associated with an activator of transcription; for the treatment of cell proliferation defects; antiproliferative agents; anticarcinogenic agents
12/26/2000US6165790 Antisense modulation of PI3 kinase p55 gamma expression
12/26/2000US6165788 Antisense modulation of Survivin expression
12/26/2000US6165774 Culturing virus in cells, separating out virus, solubilizing hemagglutinin-neuramidase and fusion envelope glycoproteins from virus, and coisolating and copurifying using ion exchange chromatography and hydroxyapatite matrix
12/26/2000US6165772 Simple and cost-effective preparation of vehicle for delivery of dna, rna, protein, peptide nucleic acids, or lipophilic drugs
12/26/2000US6165771 Compounds
12/26/2000US6165763 Nucleotide and amino acid sequences of enzyme from streptococcus; for drug screening of bacteriostats and bactericides
12/26/2000US6165762 Amino acid sequence of enzyme; drug screening of bactericides and bacteriostats; vaccines; diagnosis of infections
12/26/2000US6165759 Amino acid sequence; diagnosis, prophylaxis and therapy of infections; vaccines; bacteriostats; bactericides; screening of enzyme inhibitors and activators
12/26/2000US6165752 Expression system which produces polypeptide of defined amino acid sequence when present in a cell; diagnosis and therapy for creutzfeldt-jakob disease and nervous system disorders; anticarcinogenic agents
12/26/2000US6165514 Group iiia element-containing compounds mimic the beneficial biological effects of transforming growth factor beta without side effect, therefore applied directly to the bandage or dressing for wound healing
12/26/2000US6165513 Film-coated tablet for improved upper gastrointestinal tract safety
12/26/2000US6165507 Slow-release pharmaceutical formulations containing mizolastine
12/26/2000US6165506 A solid dose nanoparticulate naproxen formulation having a high rate of dissolution comprising a naproxen having specific particle size, polyvinylpyrrolidone adsorbed on the surface and an alkali agent to increase the dissolution rate
12/26/2000US6165504 Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
12/26/2000US6165498 Selecting an acrylate polymeric matrix and loratidine metabolite with antihistaminic activity for transdermal patch
12/26/2000US6165497 Subsaturated nicotine transdermal therapeutic system
12/26/2000US6165493 "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
12/26/2000US6165492 Intrauterine chemical necrosing method, composition, and apparatus
12/26/2000US6165491 Pharmaceutical composition based on estrogen and progesterone
12/26/2000US6165468 Antigenic carbohydrate linked to an immunogenic carrier
12/26/2000US6165464 Monoclonal antibodies directed to the HER2 receptor
12/26/2000US6165462 Sugar kinase
12/26/2000US6165461 Tao protein kinases and methods of use therefor
12/26/2000US6165447 Synergistic combination of about 0.003 to about 2.0% by weight triclosan and about 0.003 to about 2.0% by weight of a mixture of hexahydrocolupulone and hexahydrolupulone.
12/26/2000US6165445 Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
12/26/2000US6164282 Methods for restoring and/or enhancing accommodation in pseudo phakia
12/26/2000US6164281 Method of making and/or treating diseases characterized by neovascularization
12/26/2000US6163947 Method of making a hollow-tube brachytherapy device
12/26/2000CA2183453C Antiparasitic agents
12/26/2000CA2170322C Process for preparing sphingomyelin and ceramide from erythrocyte as a starting material and a curing agent or cosmetic formulated with ceramide
12/26/2000CA2150671C Compositions containing acyclovir-like compounds and 2'-vinyl substituted nucleoside analogs for the treatment of viral infections
12/26/2000CA2102591C Hypoglycemic agent
12/25/2000CA2475401A1 Method for the preparation of citalopram
12/23/2000CA2312432A1 Use of melatoninergic ligands to obtain pharmaceutical compositions for the prevention or treatment of pathologies in the gastrointestinal system
12/22/2000CA2291542A1 Novel composition
12/21/2000WO2000077255A1 49 human secreted proteins
12/21/2000WO2000077233A2 Complement-resistant non-mammalian dna viruses and uses thereof
12/21/2000WO2000077221A1 Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production
12/21/2000WO2000077211A1 Pyrexia-associated genes and pyrexia-associated proteins of plant
12/21/2000WO2000077207A2 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
12/21/2000WO2000077199A1 Cloning and expression of a novel 5-ht4 receptor
12/21/2000WO2000077190A2 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
12/21/2000WO2000077173A1 42 human secreted proteins
12/21/2000WO2000077169A2 (z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
12/21/2000WO2000077168A2 ANTAGONISTS OF BMP AND TGFβ SIGNALLING PATHWAYS
12/21/2000WO2000077166A2 Gene expression modulated in gastrointestinal inflammation
12/21/2000WO2000077037A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/21/2000WO2000077035A2 Novel potassium channels and genes encoding these potassium channels
1 ... 6187 6188 6189 6190 6191 6192 6193 6194 6195 6196 6197 6198 6199 6200 6201 6202 6203 6204 6205 6206 6207 ... 7860